The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis

Applied Microbiology and Biotechnology

Volumn 97, Issue 20, 2013, Pages 8841-8848

  Riccardi, Giovanna ^a   Pasca, Maria Rosalia ^a   Chiarelli, Laurent Roberto ^a   Manina, Giulia ^b   Mattevi, Andrea ^a   Binda, Claudia ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b EPFL   (Switzerland)

Author keywords

Antituberculars; DprE1; Drug target; Tuberculosis

Indexed keywords

ANTITUBERCULAR AGENTS; ANTITUBERCULARS; DPRE1; DRUG TARGETS; ENZYMATIC ACTIVITIES; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

BIOLOGY; BIOTECHNOLOGY;

ENZYME INHIBITION;

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; BACTERIAL ENZYME; BEDAQUILINE; BTZ 043; CLAVULANIC ACID; DECAPRENYLPHOSPHORYL DEXTRO RIBOSE OXIDASE 1; DNB 1; ETHAMBUTOL; ETHYL[2 (BENZO[D]THIAZOLE 2 CARBOXAMIDO)THIOPHENE 3 CARBONYL]CARBAMATE; ISONIAZID; MEROPENEM; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; NATURAL PRODUCTS AND THEIR SYNTHETIC DERIVATIVES; NITROBENZENE DERIVATIVE; NITROSO DERIVATIVE; OXIDOREDUCTASE; OXIDOREDUCTASE INHIBITOR; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TCA 1; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; VI 9376;

DRUG; ENZYME; ENZYME ACTIVITY; METABOLISM; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; BACTERIAL CELL WALL; BACTERIAL STRAIN; CELL METABOLISM; DRUG EFFICACY; DRUG FATALITY; DRUG RESISTANT TUBERCULOSIS; DRUG SCREENING; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; HUMAN; MICROBIAL GENETICS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION;

BACTERIA (MICROORGANISMS); MYCOBACTERIUM TUBERCULOSIS;

ANIMALS; BACTERIAL PROTEINS; CELL WALL; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; OXIDOREDUCTASES; TUBERCULOSIS;

EID: 84885374789     PISSN: 01757598     EISSN: 14320614     Source Type: Journal    
DOI: 10.1007/s00253-013-5218-x     Document Type: Review

References (39)

1. Andries K, Verhasselt P, Guillemont J, Göhlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V (2005) A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307:223-227
2. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, Collins D, de Lisle G, Jacobs WR Jr (1994) inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263:227-230
3. Batt SM, Jabeen T, Bhowruth V, Quill L, Lund PA, Eggeling L, Alderwick LJ, Fütterer K, Besra GS (2012) Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors. Proc Natl Acad Sci U S A 109:11354-11359
4. Carroll P, Faray-Kele MC, Parish T (2012) Identifying vulnerable pathways in Mycobacterium tuberculosis by using a knockdown approach. Appl Environ Microbiol 7:5040-5043
5. Christophe T, Jackson M, Jeon HK, Fenistein D, Contreras-Dominguez M, Kim J, Genovesio A, Carralot JP, Ewann F, Kim EH, Lee SY, Kang S, Seo MJ, Park EJ, Skovierová H, Pham H, Riccardi G, Nam JY, Marsollier L, Kempf M, Joly-Guillou ML, Oh T, Shin WK, No Z, Nehrbass U, Brosch R, Cole ST, Brodin P (2009) High content screening identifies decaprenyl-phosphoribose 2′ epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog 5:e1000645. doi: 10.1371/journal.ppat.1000645
6. Cohen J (2013) Infectious disease. Approval of novel TB drug celebrated - with restraint. Science 339:130
7. Cole ST, Riccardi G (2011) New tuberculosis drugs on the horizon. Curr Opin Microbiol 14:570-576
8. Crellin PK, Brammananth R, Coppel RL (2011) Decaprenylphosphoryl-β- d-ribose 2′-epimerase, the target of benzothiazinones and dinitrobenzamides, is an essential enzyme in Mycobacterium smegmatis. PLoS One 6:e16869. doi: 10.1371/journal.pone.0016869
9. De Jesus Lopes Ribeiro AL, Degiacomi G, Ewann F, Buroni S, Incandela ML, Chiarelli LR, Mori G, Kim J, Contreras-Dominguez M, Park YS, Han SJ, Brodin P, Valentini G, Rizzi M, Riccardi G, Pasca MR (2011) Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis. PLoS One 6:e26675. doi: 10.1371/journal.pone.0026675
10. Dye C, Glaziou P, Floyd K, Raviglione M (2013) Prospects for tuberculosis elimination. Annu Rev Public Health 34:271-286. doi: 10.1146/annurev- publhealth-031912-114431
11. Engohang-Ndong J (2012) Antimycobacterial drugs currently in Phase II clinical trials and preclinical phase for tuberculosis treatment. Expert Opin Investig Drugs 21:1789-1800
12. Fenner L, Gagneux S, Helbling P, Battegay M, Rieder HL, Pfyffer GE, Zwahlen M, Furrer H, Siegrist HH, Fehr J, Dolina M, Calmy A, Stucki D, Jaton K, Janssens JP, Stalder JM, Bodmer T, Ninet B, Böttger EC, Egger M, Swiss HIV Cohort Study Group, Molecular Epidemiology of Tuberculosis Study Group (2012) Mycobacterium tuberculosis transmission in a country with low tuberculosis incidence: role of immigration and HIV infection. J Clin Microbiol 50:388-395
13. Forneris F, Heuts DP, Delvecchio M, Rovida S, Fraaije MW, Mattevi A (2008) Structural analysis of the catalytic mechanism and stereoselectivity in Streptomyces coelicolor alditol oxidase. Biochemistry 47:978-985
14. Johnsson K, Schultz PG (1994) Mechanistic studies of the oxidation of isoniazid by the catalase peroxidase from Mycobacterium tuberculosis. J Am Chem Soc 116:7425-7426
15. Lechartier B, Hartkoorn RC, Cole ST (2012) In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 56:5790-5793
16. Li H, Jogl G (2013) Crystal structure of decaprenylphosphoryl-β-d- ribose 2′-epimerase from Mycobacterium smegmatis. Proteins 81:538-543
17. Lu XY, You QD, Chen YD (2010) Recent progress in the identification and development of InhA direct inhibitors of Mycobacterium tuberculosis. Mini Rev Med Chem 10:181-192
18. Magnet S, Hartkoorn RC, Székely R, Pató J, Triccas JA, Schneider P, Szántai-Kis C, Orfi L, Chambon M, Banfi D, Bueno M, Turcatti G, Kéri G, Cole ST (2010) Leads for antitubercular compounds from kinase inhibitor library screens. Tuberculosis (Edinb) 90:354-360
19. Makarov V, Manina G, Mikusova K, Möllmann U, Ryabova O, Saint-Joanis B, Dhar N, Pasca MR, Buroni S, Lucarelli AP, Milano A, De Rossi E, Belanova M, Bobovska A, Dianiskova P, Kordulakova J, Sala C, Fullam E, Schneider P, McKinney JD, Brodin P, Christophe T, Waddell S, Butcher P, Albrethsen J, Rosenkrands I, Brosch R, Nandi V, Bharath S, Gaonkar S, Shandil RK, Balasubramanian V, Balganesh T, Tyagi S, Grosset J, Riccardi G, Cole ST (2009) Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324:801-804
20. Manina G, Bellinzoni M, Pasca MR, Neres J, Milano A, Ribeiro AL, Buroni S, Skovierová H, Dianišková P, Mikušová K, Marák J, Makarov V, Giganti D, Haouz A, Lucarelli AP, Degiacomi G, Piazza A, Chiarelli LR, De Rossi E, Salina E, Cole ST, Alzari PM, Riccardi G (2010) Biological and structural characterization of the Mycobacterium smegmatis nitroreductase NfnB, and its role in benzothiazinone resistance. Mol Microbiol 77:1172-1185
21. Mikusová K, Huang H, Yagi T, Holsters M, Vereecke D, D'Haeze W, Scherman MS, Brennan PJ, McNeil MR, Crick DC (2005) Decaprenylphosphorylarabinofuranose, the donor of the d-arabinofuranosyl residues of mycobacterial arabinan, is formed via a two-step epimerization of decaprenylphosphoryl ribose. J Bacteriol 187:8020-8025
22. Neres J, Pojer F, Molteni E, Chiarelli LR, Dhar N, Boy-Röttger S, Buroni S, Fullam E, Degiacomi G, Lucarelli AP, Read RJ, Zanoni G, Edmondson DE, De Rossi E, Pasca MR, McKinney JD, Dyson PJ, Riccardi G, Mattevi A, Cole ST, Binda C (2012) Structural basis for benzothiazinone-mediated killing of Mycobacterium tuberculosis. Sci Transl Med 4:150ra121. doi: 10.1126/ scitranslmed.3004395
23. Pasca MR, Degiacomi G, Ribeiro AL, Zara F, De Mori P, Heym B, Mirrione M, Brerra R, Pagani L, Pucillo L, Troupioti P, Makarov V, Cole ST, Riccardi G (2010) Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones. Antimicrob Agents Chemother 54:1616-1618
24. Pawlowski A, Jansson M, Sköld M, Rottenberg ME, Källenius G (2012) Tuberculosis and HIV co-infection. PLoS Pathog 8:e1002464. doi: 10.1371/journal.ppat.1002464
25. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6:29-40
26. Rombouts Y, Brust B, Ojha AK, Maes E, Coddeville B, Elass-Rochard E, Kremer L, Guerardel Y (2012) Exposure of mycobacteria to cell wall-inhibitory drugs decreases production of arabinoglycerolipid related to mycolyl-arabinogalactan-peptidoglycan metabolism. J Biol Chem 287:11060-11069
27. Rozwarski DA, Grant GA, Barton DH, Jacobs WR Jr, Sacchettini JC (1998) Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 279:98-102
28. Sassetti CM, Boyd DH, Rubin EJ (2003) Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 48:77-84
29. Shi L, Sohaskey CD, Pfeiffer C, Datta P, Parks M, McFadden J, North RJ, Gennaro ML (2010) Carbon flux rerouting during Mycobacterium tuberculosis growth arrest. Mol Microbiol 78:1199
30. Stanley SA, Grant SS, Kawate T, Iwase N, Shimizu M, Wivagg C, Silvis M, Kazyanskaya E, Aquadro J, Golas A, Fitzgerald M, Dai H, Zhang L, Hung DT (2012) Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. ACS Chem Biol 7:1377137-1377184
31. Tiwari R, Moraski GC, Krchňák V, Miller PA, Colon-Martinez M, Herrero E, Oliver AG, Miller MJ (2013) Thiolates chemically induce redox activation of BTZ043 and related potent nitro aromatic anti-tuberculosis agents. J Am Chem Soc 135:3539-3549
32. Trefzer C, Rengifo-Gonzalez M, Hinner MJ, Schneider P, Makarov V, Cole ST, Johnsson K (2010) Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-β-d-ribose 2′-epimerase DprE1 of Mycobacterium tuberculosis. J Am Chem Soc 132:13663-13665
33. Trefzer C, Škovierová H, Buroni S, Bobovská A, Nenci S, Molteni E, Pojer F, Pasca MR, Makarov V, Cole ST, Riccardi G, Mikušová K, Johnsson K (2012) Benzothiazinones are suicide inhibitors of mycobacterial decaprenylphosphoryl-β-d-ribofuranose 2′-oxidase DprE1. J Am Chem Soc 134:912-915
34. Voelker R (2013) MDR-TB has new drug foe after fast-track approval. JAMA 309:430
35. Walter ND, Strong M, Belknap R, Ordway DJ, Daley CL, Chan ED (2012) Translating basic science insight into public health action for multidrug- and extensively drug-resistant tuberculosis. Respirology 17:772-791
36. Wang F, Sambandan D, Halder R, Wang J, Batt SM, Weinrick B, Ahmad I, Yang P, Zhang Y, Kim J, Hassani M, Huszar S, Trefzer C, Ma Z, Kaneko T, Mdluli KE, Franzblau S, Chatterjee AK, Johnson K, Mikusova K, Besra GS, Fütterer K, Jacobs WR Jr, Schultz PG (2013) Identification of a small molecule with activity against drug-resistant and persistent tuberculosis. Proc Natl Acad Sci U S A 110:E2510-E2517. doi: 10.1073/pnas.1309171110
37. WHO, World Health Organization (2012). http://www.who.int/en/
38. Wolucka BA (2008) Biosynthesis of d-arabinose in mycobacteria - a novel bacterial pathway with implications for antimycobacterial therapy. FEBS J 275:2691-2711
39. Zumla A, Nahid P, Cole ST (2013) Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 12:388-404. doi: 10.1038/nrd4001